The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Title |
Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis
|
---|---|
Published in |
Therapeutics and Clinical Risk Management, May 2011
|
DOI | 10.2147/tcrm.s19385 |
Pubmed ID | |
Authors |
Lisa-Ann Fraser, Kelly N Vogt, Jonathan D Adachi, Lehana Thabane |
Abstract |
The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients with primary osteoporosis have not been well established. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 20% |
Colombia | 1 | 20% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 3% |
Spain | 1 | 3% |
Unknown | 35 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 16% |
Student > Doctoral Student | 5 | 14% |
Professor > Associate Professor | 4 | 11% |
Student > Master | 4 | 11% |
Student > Postgraduate | 3 | 8% |
Other | 9 | 24% |
Unknown | 6 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 65% |
Nursing and Health Professions | 2 | 5% |
Social Sciences | 1 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Unknown | 9 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2020.
All research outputs
#6,275,904
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#303
of 1,323 outputs
Outputs of similar age
#34,491
of 121,549 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 5 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,549 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.